Live attenuated Japanese encephalitis virus + Live attenuated Japanese encephalitis virus + Live attenuated Japanese encephalitis virus + ChimeriVax™ diluent (Placebo)
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Japanese Encephalitis
Conditions
Japanese Encephalitis
Trial Timeline
Nov 1, 2004 → Nov 1, 2007
NCT ID
NCT00981630About Live attenuated Japanese encephalitis virus + Live attenuated Japanese encephalitis virus + Live attenuated Japanese encephalitis virus + ChimeriVax™ diluent (Placebo)
Live attenuated Japanese encephalitis virus + Live attenuated Japanese encephalitis virus + Live attenuated Japanese encephalitis virus + ChimeriVax™ diluent (Placebo) is a phase 2 stage product being developed by Sanofi for Japanese Encephalitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00981630. Target conditions include Japanese Encephalitis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00981630 | Phase 2 | Completed |
Competing Products
20 competing products in Japanese Encephalitis